<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02017613</url>
  </required_header>
  <id_info>
    <org_study_id>RP6530-1301</org_study_id>
    <secondary_id>2013-003769-32</secondary_id>
    <nct_id>NCT02017613</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies</brief_title>
  <acronym>PI3K</acronym>
  <official_title>A Phase I, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual PI3K Delta/Gamma Inhibitor, in Patients With Relapsed or Refractory Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rhizen Pharmaceuticals SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rhizen Pharmaceuticals SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and efficacy of RP6530, a dual PI3K
      delta/gamma inhibitor in patients with hematologic malignancies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Maximum tolerated dose (MTD) will be determined based on the safety, pharmacokinetic (PK)
      and efficacy data. Safety analyses include AE's, AE's related to the drug, SAE's, laboratory
      values, vitals/ ECG and dose limiting toxicity (DLT). PK include measurement of peak plasma
      concentration (Cmax), area under the plasma concentration versus the time curve (AUC), time
      of maximum concentration observed (Tmax). Efficacy analyses include overall response rate
      (ORR) and duration of response (DOR).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) and pharmacokinetics (PK) of RP6530</measure>
    <time_frame>28 days</time_frame>
    <description>To access maximum tolerated dose by clinical laboratory assessments, adverse events and dose limiting toxicities.
PK parameter AUC, Cmax, tmax, t1/2 will be determined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response following administration of RP6530</measure>
    <time_frame>8 weeks</time_frame>
    <description>Overall response rate (ORR) and duration of response (DOR).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Lymphoma, B-Cell</condition>
  <condition>T-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RP6530 administered orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RP6530</intervention_name>
    <description>Escalating doses starting at 25 mg BID</description>
    <arm_group_label>Single arm</arm_group_label>
    <other_name>PI3k Delta/ Gamma inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Refractory to or relapsed after at least 1 prior treatment line.

          -  ECOG performance status ≤2

          -  Patients must be ≥18 years of age

          -  Able to give a written informed consent.

        Exclusion Criteria:

          -  Any cancer therapy in the last 4 weeks or limited palliative radiation &lt;2 weeks

          -  Patients with HBV, HCV or HIV infection

          -  Autologous hematologic stem cell transplant within 3 months of study entry. Allogeneic
             hematologic stem cell transplant within 12 months.

          -  Previous therapy with GS-1101 (CAL-101, idelalisib), IPI-145, TGR-1202 or any drug
             that specifically inhibits PI3K/ mTOR (including temsirolimus, everolimus), AKT or BTK
             Inhibitor (including Ibrutinib).

          -  Patients on immunosuppressive therapy including systemic corticosteroids.

          -  Patients who are receiving chronic systemic anticoagulation therapy (warfarin sodium
             or heparin, etc.).

          -  Patients with known history of liver disorders.

          -  Patients with uncontrolled Diabetes Type I or Type II

          -  Any severe and/or uncontrolled medical conditions or other conditions that could
             affect their participation in the study.

          -  Women who are pregnant or lactating.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrés JM Ferreri, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ospedale San Raffaele s.r.l.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carmelo Carlo-stella, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Humanitas Clinical and Research Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Delarue, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Necker-Enfants Malades</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rhizen Trial Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhizen Trial Site 1</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhizen Trial Site 2</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2013</study_first_submitted>
  <study_first_submitted_qc>December 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2013</study_first_posted>
  <last_update_submitted>June 23, 2016</last_update_submitted>
  <last_update_submitted_qc>June 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CLL, SLL, NHL, SLL, PTCL, CTCL, MM, AML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

